Strategies for Generic Topical Product Development (7of35) Complex Generics– Sep. 25-26, 2019

Quality for Transdermal Delivery Systems (8of35) Complex Generic Drugs – Sep. 25-26, 2019

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

Complex Generics: Topical Products, Part 1

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

Bioequivalence for Generic Topical and Transdermal (6of35) Complex Generics– Sep. 25-26, 2019

Common Deficiencies with ANDAs for Topical Products: (23of39) Complex Generics 2018

FDA Expert Panel on Food Allergies

Framework for FDA’s Real-World Evidence Program – Mar 15, 2019

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA’s Rare Disease Day 2026 – An Event for Patients

FDA's Public Meeting on Food Allergen Thresholds - 02/18/2026

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

FDA Direct: Combating Rare Diseases at the FDA